Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
about
The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy-Induced Nausea and Vomiting: Systematic Review of the Literature.Evaluation of the efficacy of aprepitant on the prevention of chemotherapy-induced nausea and vomiting and quality of life with functional living index emesisFosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomitingUse of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a reviewPrevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron.Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy.Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance).Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.Aprepitant and fosaprepitant: a 10-year review of efficacy and safetyComparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice.Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer.Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.Palonosetron as an anti-emetic and anti-nausea agent in oncology.Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitantThe glucocorticoid receptor signalling in breast cancer.Management of postoperative nausea and vomiting: focus on palonosetronTreatment of Nausea and Vomiting During Chemotherapy.Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.Update on the management of chemotherapy-induced nausea and vomiting - focus on palonosetron.
P2860
Q33805465-EFD95A28-BF25-4672-98D5-18461A075019Q33974476-EF9E3D94-93B7-4DD3-8C72-0D86807A4674Q34239808-C8AE5D40-B9A8-473E-AA97-ECB955C02C46Q34417851-200C7D16-C942-4D58-A045-8A09CC7733BEQ34418451-7096D8BE-5278-4845-B3EF-CDADBF53678EQ34418467-1FEDDD1B-B05F-4FE7-8832-4075905663EBQ34458672-B865A3CB-4102-477C-A7A2-E0030FD7BC2BQ34775395-9341E45C-9F7F-4688-9196-BB09240B46E4Q35082647-9BEDFABA-26D6-493E-82D1-BC5D075E03B6Q35345557-E126178C-07B9-406D-8F78-9AB5A58D2AF4Q35854847-6CE92B32-52E3-4038-99C8-906705DEA440Q36205615-9CB92C45-CF7E-462E-835C-1A80CBA0B33AQ36510947-5160CAF3-7EA3-4814-96D6-FB8F49F84899Q36663660-3E2985DD-69DD-4F0C-97A7-1A8C17D13410Q36823546-424577A3-77D8-4EBF-84A9-6AF3F6095D9DQ37021452-342D1B52-A0BF-40AD-A9D3-184FB99DF61DQ37230293-48D007D7-60AF-4EF6-8DC9-80926547796FQ37503489-F60DAD7D-79C9-4FD8-879F-ACAA939B351BQ37609798-7ECFEFD7-0514-41BC-90C6-0D698CF0210FQ38497106-7DB6B55C-D054-4F7A-B269-DE46DC753BF6
P2860
Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Combination therapy for chemot ...... dexamethasone, and aprepitant.
@en
Combination therapy for chemot ...... dexamethasone, and aprepitant.
@nl
type
label
Combination therapy for chemot ...... dexamethasone, and aprepitant.
@en
Combination therapy for chemot ...... dexamethasone, and aprepitant.
@nl
prefLabel
Combination therapy for chemot ...... dexamethasone, and aprepitant.
@en
Combination therapy for chemot ...... dexamethasone, and aprepitant.
@nl
P2093
P1476
Combination therapy for chemot ...... dexamethasone, and aprepitant
@en
P2093
Alan Cartmell
Angela Ginkel
Julio Hajdenberg
Susan Ferguson
Thomas Grote
Veena Charu
P304
P577
2006-09-01T00:00:00Z